Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 1
1954 6
1955 6
1956 12
1957 10
1958 3
1963 1
1964 7
1965 107
1966 208
1967 247
1968 248
1969 278
1970 237
1971 301
1972 428
1973 427
1974 406
1975 438
1976 419
1977 397
1978 358
1979 367
1980 380
1981 371
1982 404
1983 412
1984 477
1985 524
1986 522
1987 544
1988 456
1989 522
1990 588
1991 608
1992 620
1993 711
1994 740
1995 670
1996 663
1997 690
1998 587
1999 626
2000 631
2001 609
2002 622
2003 614
2004 616
2005 581
2006 588
2007 580
2008 557
2009 605
2010 587
2011 657
2012 669
2013 599
2014 619
2015 623
2016 590
2017 611
2018 569
2019 623
2020 562
2021 427
2022 388
2023 274
2024 465
2025 331
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28,927 results

Results by year

Filters applied: . Clear all
Page 1
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Šimkovič M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. Brown JR, et al. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. Epub 2025 Feb 5. N Engl J Med. 2025. PMID: 39976417 Clinical Trial.
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Kennedy B, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P; UK CLL Trials Group. Munir T, et al. N Engl J Med. 2025 Sep 25;393(12):1177-1190. doi: 10.1056/NEJMoa2504341. Epub 2025 Jun 15. N Engl J Med. 2025. PMID: 40521799 Free article. Clinical Trial.
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
Valgimigli M, Hong SJ, Gragnano F, Chalkou K, Franzone A, da Costa BR, Baber U, Kim BK, Jang Y, Chen SL, Stone GW, Hahn JY, Windecker S, Gibson MC, Song YB, Ge Z, Vranckx P, Mehta S, Gwon HC, Lopes RD, Dangas GD, McFadden EP, Angiolillo DJ, Leonardi S, Heg D, Calabrò P, Jüni P, Mehran R, Hong MK; Single Versus Dual Antiplatelet Therapy (Sidney-4) collaborator group. Valgimigli M, et al. Lancet. 2024 Sep 7;404(10456):937-948. doi: 10.1016/S0140-6736(24)01616-7. Epub 2024 Aug 31. Lancet. 2024. PMID: 39226909
Selective modulation of epileptic tissue by an adenosine A3 receptor-activating drug.
Ghosh A, Ribeiro-Rodrigues L, Ruffolo G, Alfano V, Domingos C, Rei N, Tosh DK, Rombo DM, Morais TP, Valente CA, Xapelli S, Bordadágua B, Rainha-Campos A, Bentes C, Aronica E, Diógenes MJ, Vaz SH, Ribeiro JA, Palma E, Jacobson KA, Sebastião AM. Ghosh A, et al. Br J Pharmacol. 2024 Dec;181(24):5041-5061. doi: 10.1111/bph.17319. Epub 2024 Sep 19. Br J Pharmacol. 2024. PMID: 39300608
28,927 results
You have reached the last available page of results. Please see the User Guide for more information.